EHA 2016: How the treatment of ALL is changing

EHA 2016: How the treatment of ALL is changing

VJHemOnc

3 years
505 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robin Foà, MD from the Sapienza University, Rome, Italy discusses the advances in the diagnostics and treatment of acute lymphocblastic leukemia (ALL) at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Prof. Foà first talks about changes in diagnostics and how biological stratification is becoming more sophisticated. For example, patients should be tested for Philadelphia chromosome-positive (Ph+) ALL at presentation and if tested positive, should receive a different therapy with tyrosine kinase inhibitors targeting the specific abnormality. Further, the monitoring of minimal residual disease (MRD) is now guding treatment in clinical trials, which determines decisions such as whether a patient should receive a transplant. Prof. Foà also discusses new drugs such as rituximab, which is an monoclonal anti-CD20 antibody, and blinatumomab, which is a bispecific monoclonal antibody. He also discusses the possibility of a chemotherapy-free treatment for ALL, and specifically talks about the example of Ph+ ALL. According to Prof. Foà, every Ph+ ALL patient can go into remission with an inhibitor. He further talks about an upcoming trial with ALL patients 18 or older, that will explore the use of a second-generation tyrosine kinase inhibitor and blinatumomab (NCT02744768). Finally, he discusses the potential of immunotherapy, including CAR T-cells. Prof. Foà concludes that we have entered an exciting time for ALL.
Up Next Autoplay
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
1 Views
Cancer-News 1 hour
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
0 Views
kidneycancer 3 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 3 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
1 Views
kidneycancer 22 hours
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 1 day
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
4 Views
kidneycancer 2 days
Kidney Cancer Program & SPORE
Kidney Cancer Program & SPORE
Category: Kidney Cancer
1 Views
kidneycancer 2 days